ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 223

Correlation Between Heart Rate Variability Parameters and Circulating Neuropeptides in Fibromyalgia

Laura Aline Martínez-Martínez1, Claudia Lerma Gonzalez 2, María del Carmen Navarro Gonzalez 3, Oscar Infante Vázquez 4, Felipe Israel López Trejo 5, Evelyn Aranda Cano 5, Alfonso Salgado Aguayo 3, Daniel Paz Gómez 3, María Isabel Barrera Villalpando 6, Luis Silveira 7, Violeta Higuera Ortiz 8, Angélica Vargas Guerrero 5 and Manuel Martínez-Lavín 9, 1Departamento de Reumatologia del Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 2Departamento de Instrumentación del Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, 3Laboratorio de Investigación en Enfermedades Reumáticas del Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, Mexico, 4Departamento de Instrumentación del Instituto Nacional de Cardiología Ignacio Chávez, Mexico Ciity, Mexico, 5Departamento de Reumatología del Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, 6Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico, 7Departamento de Reumatología, Instituto Nacional de Cardiología "Ignacio Chávez", Ciudad de México, México., Mexico, Mexico, 8Hospital General de Zona y Medicina Familiar 8 del Instituto Mexicano del Seguro Social, Mexico City, Mexico, 9Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: beta-endorphin and neurotensin, fibromyalgia, heart rate variability, neuropeptides

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Fibromyalgia & Other Clinical Pain Syndromes Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Heart rate variability analyses in fibromyalgia patients have shown changes consistent with sympathetic hyperactivity that theoretically could lead to chronic pain. There is little investigation on dysautonomia associated circulating neuropeptides in fibromyalgia. There are no studies correlating serum neuropeptide levels with heart rate variability parameters. The purpose of this study was to measure dysautonomia-associated serum neuropeptides levels in women with fibromyalgia and in age, sex, body mass index comparable healthy controls. Additionally to correlate neuropeptide levels with heart rate variability parameters and disease severity.

Methods: We studied 23 women with fibromyalgia without comorbid conditions and 15 matched healthy controls. At the time of the study, patients were free from medications that could affect autonomic-related neuropeptide levels. Time domain parameters were extracted from 24 hours heart rate variability recording. All participants filled out the Revised Fibromyalgia Impact Questionnaire (FIQR), Widespread Pain Index (WPI), Symptom Severity Scale (SSS), Polysymptomatic Distress Scale (PDS) and the Small Fiber Neuropathy Symptoms Survey (SFNSS). The following 7 neuropeptides levels were measured using the 7-Plex Human Neuropeptide Magnetic KitMilliplex MAP: aMSH, beta-endorphin, cortisol, neurotensin, orexin, oxytocin and substance P. The protocol was approved by the institution review board and required a written informed consent from participants. Kolmorogov-Smirnov test was used for normality analysis, Student’s T test or Mann Whitney U test for comparisons and Pearson or Spearmen test for correlations. SPSS version 23.0 was used for the analyses.

Results: Beta-endorphin (669.24 ± 186.28 vs 541.71 ± 146.26pg/ml, p=0.028) and neurotensin (156.23 ± 58.15 vs 116.64 ± 47.93pg/ml, p=0.016) levels were higher in fibromyalgia patients. Both neuropeptides levels had a negative correlation with heart rate RR interval standard deviation (Rho -0.5 and Rho -0.6, p< 0.05) and with FIQR “tenderness to touch” (Rho -0.4 and Rho -0.4, p< 0.05).

Conclusion: Heart rate variability parameters suggesting sympathetic hyperactivity correlate with circulating beta-endorphin and neurotensin levels in fibromyalgia patients.  Future research will define the possible clinical implications of this novel finding.


Disclosure: L. Martínez-Martínez, None; C. Lerma Gonzalez, None; M. Navarro Gonzalez, None; O. Infante Vázquez, None; F. López Trejo, None; E. Aranda Cano, None; A. Salgado Aguayo, None; D. Paz Gómez, None; M. Barrera Villalpando, None; L. Silveira, None; V. Higuera Ortiz, None; A. Vargas Guerrero, None; M. Martínez-Lavín, None.

To cite this abstract in AMA style:

Martínez-Martínez L, Lerma Gonzalez C, Navarro Gonzalez M, Infante Vázquez O, López Trejo F, Aranda Cano E, Salgado Aguayo A, Paz Gómez D, Barrera Villalpando M, Silveira L, Higuera Ortiz V, Vargas Guerrero A, Martínez-Lavín M. Correlation Between Heart Rate Variability Parameters and Circulating Neuropeptides in Fibromyalgia [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/correlation-between-heart-rate-variability-parameters-and-circulating-neuropeptides-in-fibromyalgia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/correlation-between-heart-rate-variability-parameters-and-circulating-neuropeptides-in-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology